Form 4: Jasper Therapeutics COO Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Jasper Therapeutics' Chief Operating Officer, Jeetinder Singh Mahal, exercised stock options and sold shares on December 12, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Jeetinder Singh Mahal, the Chief Operating Officer of Jasper Therapeutics, executed a stock option to acquire 900 shares of voting common stock at a price of $7.10 per share on December 12, 2024.
- On the same day, Mr. Mahal sold 900 shares of voting common stock at a price of $22.11 per share.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 15, 2023.
- Following these transactions, Mr. Mahal directly owns 25,009 shares of voting common stock and 13,772 stock options.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating routine insider trading activity under a pre-arranged plan. There is no indication of positive or negative sentiment.
Industry Context
This is a routine filing related to insider trading activity, which is common for executives of publicly traded companies. The use of a 10b5-1 plan indicates a pre-planned strategy for trading company stock.
Comparison to Industry Standards
- The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies to avoid accusations of insider trading.
- The reported transactions are typical for executives exercising stock options and selling shares for personal financial management.
- Similar filings are regularly made by executives at companies like Amgen, Gilead, and Regeneron, reflecting standard practices in the biotech industry.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they are part of a pre-planned trading strategy.
- The sale of shares by the COO may slightly increase the available float of the stock.
Key Dates
| Date | Description |
|---|---|
| 2020-12-12 | 25% of the original number of shares subject to the option vested. |
| 2023-03-15 | The Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 2024-12-12 | The COO exercised stock options and sold shares. |
| 2030-05-31 | Expiration date of the stock options. |
Keywords
stock options, insider trading, Form 4, Rule 10b5-1, Jasper Therapeutics, JSPR, equity securities, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.